In this issue:
- COVID-19 outcomes with IMID and therapies
- T-cell response to SARS-CoV-2 vaccination in IBD
- TNF inhibitors and risk of COVID-19 hospitalisation or death
- Antibody-based immunotherapy strategies for COVID-19
- Intestinal diversion for distal CD
- Pancreatic involvement in IBD
- Risk of IBD diagnosis after IBD associated ocular inflammation
- Food-related quality of life with IBD
- Adalimumab and infliximab impair SARS-CoV2 antibody responses
- Science blog: GM-CSF and Crohn’s disease
Please login below to download this issue (PDF)